Evommune has raised over $130 million in previous funding rounds and is expecting three Phase 2 readouts in urticaria and eczema over the next two years.
Founders
Luis Pena
Company Description
Evommune is a biotechnology startup focused on developing drugs for chronic immune conditions, specifically targeting mast cell-driven diseases. The company is advancing a pipeline of therapies, including EVO756 for chronic urticaria and EVO301 for atopic dermatitis.